Editor's Note: the "Trending USA Stocks" column tracks the day's top bullish stocks in the USA market, aiding investors in promptly identifying opportunities for potential gains.

24/08/2026 Eastern Time in USA The Dow Jones Industrial Average rose by 0.26%, closing at 53417.16 points; the Nasdaq Composite dropped by 0.76%, closing at 25980.19 points; the S&P 500 Index dropped by 0.28%, closing at 7652.86 points. Sahm has compiled the Top 10 Daily Stock Price Gainers in the USA market.

SuperX AI Technology: Overnight gain 23.7%, Surges Amid Strong Server Order Momentum and Oversold Rebound in Japan Operations

SuperX AI Technology Limited Offers End-to-End AI Infrastructure Solutions Through Singapore-Based Subsidiaries SuperX AI Technology Limited (the "Company") was incorporated in the British Virgin Islands on August 25, 2021, and operates as a dedicated provider of artificial intelligence infrastructure solutions. The Company delivers proprietary hardware, advanced software, and comprehensive end-to-end services to AI data centers through its two wholly-owned Singapore-based subsidiaries, SuperX Industries Pte. Ltd. and SuperX AI Pte. Ltd. The Company's core product and service portfolio encompasses high-performance AI servers, high-voltage direct current (HVDC) solutions, high-density liquid cooling systems, as well as AI cloud and AI agent services. In addition, the Company provides a full spectrum of value-added services, including solution design and planning, infrastructure integration, and ongoing operations and maintenance support. Headquartered in Singapore, SuperX AI Technology Limited serves a diversified global client base comprising enterprises, research institutions, and customers engaged in cloud and edge computing deployments.

SuperX AI Technology (SUPX) Surges 23.7% on Robust Order Pipeline and Operational Milestones Shares of SuperX AI Technology (SUPX) rallied 23.7% as the company reported significant business momentum at its Japan Global Supply Center. Within 2026, SUPX has successfully executed four rounds of Pro6000 server procurement orders with Digital Dynamic Inc. (DDI). Cumulative shipments reached approximately $31 million as of August 19, with projections of $38 million by month-end. Additionally, roughly $28 million in projects are under progressive delivery, while newly secured orders totaling approximately $20 million further strengthen the backlog, materially enhancing revenue visibility. Concurrently, SuperX AI Technology (SUPX)'s Japan Global Supply Center has established an integrated service framework encompassing warehousing, logistics dispatch, and local fulfillment, signaling the localized operations have entered a scalable phase. The substantial operational progress, combined with the stock's year-to-date decline of approximately 32.8%, collectively catalyzed the sharp intraday rebound.

Alvotech: Overnight gain 18.5%, Surges Amid Buy Rating, Strong Guidance, and New Licensing Deal

Alvotech: A Global Biosimilar Powerhouse Driving Accessible Biologics Innovation Alvotech was incorporated under the laws of the Grand Duchy of Luxembourg on August 23, 2021, and was founded by Robert Wessman. The Company is a dedicated biopharmaceutical enterprise focused on the research, development, and manufacturing of biosimilars on a global scale. Leveraging a fully integrated operational model and robust in-house research and development capabilities, Alvotech is committed to delivering high-quality, cost-effective products and services to patients worldwide, with the strategic ambition of establishing itself as a global leader in the biosimilar sector. The Company currently maintains a diversified product pipeline comprising eight biosimilar drug candidates, targeting a broad spectrum of therapeutic areas, including autoimmune diseases, ophthalmic conditions, osteoporosis, respiratory disorders, and oncology. This expansive pipeline underscores Alvotech's commitment to addressing significant unmet medical needs across multiple high-prevalence disease categories, positioning the Company for sustained long-term growth in the rapidly evolving global biosimilars market.

Alvotech(ALVO) Shares Rally on Confluence of Positive Catalysts Shares of Alvotech(ALVO) surged amid a convergence of multiple bullish developments. Bank of America Securities analyst Jason Gerberry initiated coverage with a Buy rating and a $7 price target, noting that the FDA has closed its inspection of the company's Reykjavik manufacturing facility, effectively eliminating a critical regulatory overhang. Gerberry also highlighted upcoming biosimilar launches, including Simponi, Eylea SD, and Entyvio candidates. Additionally, Alvotech(ALVO) reaffirmed its FY2026 revenue guidance of $650M–$700M, surpassing consensus estimates of $644.8M. Further bolstering sentiment, the company announced a licensing and commercialization agreement with Taiwan-based Lotus Pharmaceutical, covering biosimilar candidates AVT34 and AVT87, with a potential deal value of up to approximately $150 million. Notably, this marks Alvotech(ALVO)'s first direct participation in U.S. market commercialization.

The Top 10 Daily Gainers in the USA market are listed as follows: